Tonmya: Phase III started

Tonix began the double-blind, placebo-controlled, U.S. Phase III RE-AFFIRM trial to evaluate 2.8 mg TNX-102 SL once daily at bedtime for 12 weeks in about 500 patients. The company expects data from t...